Might the beneficial effects of statin drugs be related to their action on iron metabolism?

QJM: An International Journal of Medicine

Volumn 105, Issue 12, 2012, Pages 1225-1229

  Mascitelli, L ^a   Goldstein, M R ^b  

^a Medical Service   (Italy)

^b NCH Healthcare Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG MECHANISM; HUMAN; IRON METABOLISM; PRIORITY JOURNAL;

EID: 84870327188     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcs204     Document Type: Article

References (39)

1. Roberts WC. Atherosclerosis: its cause and its prevention. Am J Cardiol 2006; 98:1550-5.
2. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991; 11:290-7.
3. Sullivan JL. Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. Am Heart J 2003; 145:190-4.
4. Kannel WB, Levy D. Menopause, hormones, and cardiovascular vulnerability in women. Arch Intern Med 2004; 164:479-81.
5. Mascitelli L, Goldstein MR, Pezzetta F. Explaining sex difference in coronary heart disease: is it time to shift from the oestrogen hypothesis to the iron hypothesis? J Cardiovasc Med (Hagerstown) 2011; 12:64-5.
6. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; 1:1293-4.
7. Sullivan JL, Mascitelli L. Current status of the iron hypothesis of cardiovascular diseases. Recenti Prog Med 2007; 98:373-7.
8. Sullivan JL. Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochim Biophys Acta 2009; 1790:718-23.
9. Zhang WJ, Wei H, Frei B. The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice. Exp Biol Med 2010; 235:633-41.
10. Mascitelli L, Pezzetta F, Goldstein MR. Reduced body iron stores and atherosclerosis in patients with cyanotic congenital heart disease. Int J Cardiol 2011; 146:117.
11. Mascitelli L, Pezzetta F. Cardiovascular protections in severely impaired hemostasis. Circulation 2004; 110:e39.
12. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med 2007; 232:1014-20.
13. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006; 26:323-42.
14. Sullivan JL. Do hemochromatosis mutations protect against iron-mediated atherogenesis? Circ Cardiovasc Genet 2009; 2:652-7.
15. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 2006; 145:520-30.
16. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012; 5:2-5.
17. Mascitelli L, Pezzetta F, Goldstein MR. Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence. Arch Med Res 2010; 41:649-50.
18. Lin HL, Xu XS, Lu HX, Zhang L, Li CJ, Tang MX, et al. Pathological mechanisms and dose dependency of erythrocyte-induced vulnerability of atherosclerotic plaques. J Mol Cell Cardiol 2007; 43:272-80.
19. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 2006; 86:583-650.
20. Naito Y, Takagi T, Uchiyama K, Yoshikawa T. Heme oxygenase-1: a novel therapeutic target for gastrointestinal diseases. J Clin Biochem Nutr 2011; 48:126-33.
21. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 2010; 50:323-54.
22. Durante W. Protective role of heme oxygenase-1 against inflammation in atherosclerosis. Front Biosci 2012; 17:2372-88.
23. Poss KD, Tonegawa S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc Natl Acad Sci USA 1997; 94:10919-24.
24. Orozco LD, Kapturczak MH, Barajas B, Wang X, Weinstein MM, Wong J, et al. Heme oxygenase-1 expression in macrophages plays a beneficial role in atherosclerosis. Circ Res 2007; 100:1703-11.
25. Berglund L, Galbraith RA, Emtestam L, Drummond GS, Angelin B, Kappas A. Heme oxygenase inhibitors transiently increase serum ferritin concentrations without altering other acute-phase reactants in man. Pharmacology 1999; 59:51-6.
26. Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 2007; 40:575-84.
27. Chen JC, Huang KC, Lin WW. HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways. Cell Signal 2006; 18:32-9.
28. Ali F, Hamdulay SS, Kinderlerer AR, Boyle JJ, Lidington EA, Yamaguchi T, et al. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost 2007; 5:2537-46.
29. Mrad MF, Mouawad CA, Al-Hariri M, Eid AA, Alam J, Habib A. Statins modulate transcriptional activity of heme-oxygenase-1 promoter in NIH 3T3 cells. J Cell Biochem 2012; 113:3466-75.
30. Arabul M, Gullulu M, Yilmaz Y, Akdag I, Kahvecioglu S, Eren MA, et al. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. Clin Biochem 2008; 41:1055-8.
31. Chang CC, Chiu PF, Chen HL, Chang TL, Chang YJ, Huang CH. Simvastatin downregulates the expression of hepcidin and erythropoietin in HepG2 cells. Hemodial Int, doi: 10.1111/j.1542-4758.2012.00716.x [Epub 20 June 2012].
32. Mantuano E, Santi S, Filippi C, Manca-Rizza G, Paoletti S, Consani C, et al. Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide (LPS) stimulated production by isolated human monocytes from chronic kidney disease patients. Biomed Pharmacother 2007; 61:360-5.
33. Li JJ, Meng X, Si HP, Zhang C, Lv HX, Zhao YX, et al. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol 2012; 32:1158-66. Erratum in: Arterioscler Thromb Vasc Biol 2012; 32:e50.
34. DePalma RG, Hayes VW, Chow BK, Shamayeva G, May PE, Zacharski LR. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial. J Vasc Surg 2010; 51:1498-503.
35. Stehbens WE. Coronary heart disease, hypercholesterolemia and atherosclerosis. I. False premises. Exp Mol Pathol 2001; 70:103-19.
36. Mascitelli L, Pezzetta F, Goldstein MR. Why the overstated beneficial effects of statins do not resolve the cholesterol controversy. QJM 2009; 102:435-6.
37. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J 2011; 162:949-57.e1.
38. Mascitelli L, Goldstein MR. Statins in dermatology: is nonmelanoma skin cancer the dark side of the moon? Int J Dermatol, doi: 10.1111/j.1365-4632.2011.05067.x [Epub 18 April 2012].
39. Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis, doi: 10.1016/j.numecd.2012.04.012 [Epub 28 June 2012].